News : phase II

Leading contract research provider, Syntagon, is delighted to announce that it has entered into a collaborative agreement with world-class Quality Assurance (QA) expert George Köllner.
George brings with him more than 20 years’ experience from the pharma industry. He has served as Director of Quality Assurance at AstraZeneca where he led the development and implementation of modern Quality Assurance systems in...

Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study. MOB-015 is the company’s second-generation topical treatment for nail fungus.
The purpose of the study, which includes 237 patients, is to confirm the validity of the MOB-015 product concept and to provide the basis for a phase III program...

The Swedish Medical Products Agency has granted Moberg Derma permit to initiate a clinical phase II trial for MOB-015. MOB-015 is Moberg Dermas next generation topical treatment for nail fungus, with fungicidal, keratolytic and emollient properties.
Nail fungus (onychomycosis) chiefly manifests itself in thickening and discoloration of the nails. The disease is common, affecting about 100 million patients in...

Leading contract research organisation, Syntagon, has unveiled a strategic pricing initiative that will see substantial cost savings for biotechnology and pharmaceutical customers taking compounds into phase I and phase II clinical trials.
“Now, more than ever, customers are under growing pressure to make their limited resources stretch further. Cost-efficiency is increasingly critical; and maintaining cash is...

Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in...